Dementia blood sits at the center of this dementia and brain health question.

A newly validated blood test can identify dementia risk up to 25 years before symptoms appear—but doctors currently don’t recommend that healthy women over 45 get screened with it. This distinction matters. A March 2026 study from UC San Diego found that phosphorylated tau 217 (p-tau217), a protein biomarker measurable in blood, can predict who will develop dementia decades in advance.

Women with the highest p-tau217 levels showed approximately 7 times higher dementia risk compared to those with the lowest levels. Yet despite this promise, major medical organizations including Mayo Clinic and the Alzheimer’s Association do not recommend routine blood testing for asymptomatic people—even those over 45. The blood tests that have received FDA approval are intended for people aged 50 and older who already have cognitive symptoms like memory loss or thinking problems. This article explores what the new research shows, what tests are actually available, what they can and cannot do, and why the gap between promising science and clinical recommendation matters for your health decisions.

What Is Phosphorylated Tau 217 and Why Do Doctors Care About It?
How Accurate Is This Blood Test for Predicting Dementia?
Which Blood Tests Are FDA-Approved and What Are They For?
Why Don’t Doctors Recommend This Test for Every Woman Over 45?
When Should You Actually Ask Your Doctor About This Blood Test?
The Research-to-Practice Timeline: Why Promising Science Doesn’t Automatically Become Standard Screening
The Future of Dementia Blood Biomarkers and What Might Change
Conclusion

What Is Phosphorylated Tau 217 and Why Do Doctors Care About It?

Tau is a protein naturally present in the brain. In Alzheimer’s disease and other dementia conditions, tau proteins become abnormally phosphorylated—chemically modified—and begin clumping together, damaging brain cells and impairing cognitive function. For decades, detecting abnormal tau required expensive, invasive procedures like cerebrospinal fluid sampling or PET imaging.

Phosphorylated tau 217 (p-tau217) is a specific form of this damaged protein that researchers discovered can leak into the bloodstream at very low levels, making it detectable through a simple blood test. The UC San Diego study tracked women over extended periods and found that p-tau217 levels in blood strongly predicted who would develop Alzheimer’s dementia—with some women showing predictive accuracy up to 25 years before cognitive decline became noticeable. This represents a major technical breakthrough: for the first time, doctors have a non-invasive, affordable way to identify brain pathology years before a patient experiences symptoms.

What Is Phosphorylated Tau 217 and Why Do Doctors Care About It?

How Accurate Is This Blood Test for Predicting Dementia?

The research is genuinely striking. Women with the highest p-tau217 levels in the UC San Diego study had approximately 7 times higher dementia risk compared to women with the lowest levels. In some cases, the p-tau217 model could predict symptom onset within 3 to 4 years—moving from a 25-year window down to a much shorter, more actionable timeframe. However, there’s a critical limitation: the test predicts risk, but it does not diagnose Alzheimer’s disease.

A positive p-tau217 result means the brain shows pathological changes, but not everyone with those changes will develop dementia during their lifetime. Some people with evidence of tau accumulation remain cognitively intact for decades. Blood tests also cannot stand alone; they must be interpreted by specialists alongside cognitive testing, neurological exams, and MRI imaging. If your test comes back elevated but you have no memory loss or thinking problems, that result requires careful discussion with a neurologist about what it means for you specifically—not immediate treatment.

Which Blood Tests Are FDA-Approved and What Are They For?

Two main blood tests have received FDA clearance for Alzheimer’s-related pathology. In May 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio for clinical diagnosis of Alzheimer’s disease. In October 2025, the FDA cleared Roche’s Elecsys pTau181 as the first blood test approved for primary care use—specifically to rule out Alzheimer’s-related amyloid pathology in patients who already have cognitive symptoms.

The tests range in cost from $290 to $1,150, depending on the specific test and clinical context. Quest Diagnostics offers an AD-Detect test for $399 plus a $13 physician service fee, and notably, some blood tests can be ordered without a doctor’s direct involvement. The critical point: these FDA approvals specifically state the tests are intended for adults aged 50 and older who present with cognitive symptoms like memory loss, confusion, or thinking difficulties—not for routine screening in people without symptoms.

Which Blood Tests Are FDA-Approved and What Are They For?

Current clinical guidelines from Mayo Clinic and the Alzheimer’s Association do not recommend blood tests for routine screening in asymptomatic people, including healthy women over 45. This may seem counterintuitive given the promising research, but there are sound reasons. First, positive test results can cause anxiety without clear guidance on what to do—early intervention before symptoms appears remains unproven.

Second, the test identifies pathology but not everyone with pathology develops dementia, meaning false-positive worry is common. Third, the test is designed for and approved in people 50 and older with symptoms, not younger asymptomatic individuals. Using tests outside their approved indications can create liability and doesn’t align with evidence-based practice. The research from UC San Diego is compelling and may eventually change screening recommendations, but that requires additional studies proving that early intervention based on blood biomarkers actually improves outcomes—something we don’t yet have evidence for.

When Should You Actually Ask Your Doctor About This Blood Test?

You have a reasonable conversation to initiate with your doctor if you are age 50 or older and experiencing cognitive symptoms—memory lapses beyond normal aging, difficulty concentrating, trouble finding words, or taking longer to complete familiar tasks. These are situations where a blood test for p-tau181 or p-tau217 can meaningfully inform diagnosis and guide next steps. Family history of dementia may also be relevant context to discuss, though family history alone doesn’t trigger a routine screening recommendation.

If you’re in your 40s without symptoms, current medical evidence does not support seeking out this test even if you have family history. That landscape may change as research accumulates, but for now, the guidelines are clear. One important caveat: if you have a condition that increases dementia risk—such as significant head trauma, depression, diabetes, or hypertension not well-controlled—discuss your individual risk profile with your physician rather than assuming you need screening based on age alone.

When Should You Actually Ask Your Doctor About This Blood Test?

The Research-to-Practice Timeline: Why Promising Science Doesn’t Automatically Become Standard Screening

Medical innovation moves in stages. Research discovery (like the UC San Diego p-tau217 findings) shows something works in a study. FDA approval follows for specific clinical uses (symptomatic diagnosis in adults 50+). Routine screening recommendations come last—only after broad evidence shows screening asymptomatic people saves lives or meaningfully improves outcomes.

The dementia blood tests sit at stage two: they’re approved for clinical diagnosis of people with symptoms, but we lack stage three evidence that screening asymptomatic individuals changes outcomes positively. This isn’t a flaw in the tests; it’s scientific caution. We’ve seen cases where screening apparently healthy populations for early disease led to unnecessary treatment, anxiety, and harm. Dementia research is actively addressing this—investigators are exploring whether early intervention in people with elevated biomarkers but no symptoms prevents or delays cognitive decline—but those answers won’t arrive overnight.

The Future of Dementia Blood Biomarkers and What Might Change

The trajectory of dementia detection is moving toward blood-based biomarkers as the standard. Within the next several years, as more studies like the UC San Diego research accumulate, screening recommendations may broaden. If clinical trials prove that people with elevated p-tau217 who receive early interventions—whether pharmaceutical, lifestyle-based, or both—experience delayed cognitive decline, the case for routine screening strengthens significantly.

Blood tests are cheap, non-invasive, and scalable compared to imaging or lumbar puncture, making them ideal for widespread screening once the evidence justifies it. For now, the tests represent a powerful tool for people experiencing cognitive symptoms and a promising window into future prevention strategies. The women and men who will benefit most from dementia blood tests in the immediate future are those 50 and older with noticeable cognitive changes—not the broader population of women over 45.

Conclusion

The dementia blood test measuring phosphorylated tau 217 represents a genuine breakthrough in identifying Alzheimer’s pathology decades before symptoms appear. The recent UC San Diego research showing 7-fold increased risk in women with elevated p-tau217 is compelling and may eventually reshape how we approach dementia prevention. However, the title’s promise that “every woman over 45 should ask about” this test doesn’t align with current clinical reality. Doctors don’t recommend routine screening in asymptomatic people because we lack evidence that early detection without symptoms improves outcomes, and positive results can generate anxiety without clear guidance on next steps.

The approved blood tests are most appropriately used for adults 50 and older who already have cognitive symptoms. If you’re experiencing memory loss, difficulty concentrating, or other cognitive changes, talk with your doctor about whether biomarker testing makes sense for you. If you’re healthy without symptoms, focus on proven dementia risk reduction: managing cardiovascular health, staying cognitively active, maintaining social engagement, and controlling conditions like diabetes and hypertension. This approach is evidence-based today, while routine biomarker screening awaits further research. The science of dementia detection continues to advance rapidly—but it’s advancing at the pace of evidence, not hype.